ASSEMBLY BIOSCIENCES, INC.
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
About Assembly Biosciences
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology enterprise that develops novel therapeutic candidates targeting serious viral infections. Its pipeline comprises multiple investigational treatments, including helicase-primase inhibitors for recurrent genital herpes, an oral entry inhibitor for hepatitis delta virus, and a next-generation capsid assembly modulator for chronic hepatitis B. The company also develops an oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses. Its target end users are patients suffering from severe, chronic, or recurrent viral illnesses, including immunocompromised individuals undergoing organ transplants.
The organization conducts clinical trials and research activities across multiple regions, with clinical trial filings, regulatory submissions, and study sites situated in the United States and European nations. The company also collaborates internationally with Gilead Sciences on licensing and late-stage development for select antiviral programs. The provided text contains no mention of the total number of physical operating facilities or the location of the corporate headquarters.
Summary of the business section of Assembly Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ASSEMBLY BIOSCIENCES, INC.
- Headquarters
- South San Francisco, CA
- Address
- Two Tower Place, 7th Floor 94080
- Phone
- (833) 409-4583
- Employees
- 73, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Jose, California
Stock & identifiers
- Ticker
- ASMB
- Exchange
- Nasdaq
- IPO date
- Dec 17, 2010
- Shares outstanding
- 20M, Aug 7, 2026
- Public float
- $97.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Feb 12, 2024; 1-for-12 reverse, Feb 9, 2024; 1-for-5 reverse, Aug 14, 2014; 1-for-5 reverse, Jul 14, 2014
- SEC CIK
- 1426800
- CUSIP
- 045396207
- ISIN
- US0453962070
- LEI
- 5299007Y1X8RBDFT8C40
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jason A. Okazaki | CEO and President, Director | 163,354 |
| Jeanette M. Bjorkquist | PFO and PAO | 14,560 |
| Nicole S. White | Chief Manufacturing Officer | 48,145 |
| William E. Delaney IV | Chief Scientific Officer | 60,330 |
| Anuj Gaggar | Chief Medical Officer | 42,688 |
| Susan Mahony | Director | – |
| Michael Houghton | Director | 3,202 |
| Anthony E. Altig | Director | 8,000 |
| Lisa Johnson-Pratt | Director | – |
| Gina Consylman | Director | – |
| John G. McHutchison | Director | 18,347 |
| William R. Ringo | Director | 17,465 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jason A. Okazaki | $2.48M | $5.51M | $1.26M | $218 | – |
| FY2024 Jason A. Okazaki | $1.77M | $2.15M | $895.50K | $101 | – |
| FY2023 Jason A. Okazaki | $1.37M | $1.13M | $758.67K | $63 | – |
| FY2022 Jason A. Okazaki | $1.76M | $1.32M | $1.61M | $21 | – |
| FY2021 Jason A. Okazaki | $2.87M | $1.08M | $1.15M | $39 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 73 total employees and contracts with a number of temporary contractors, consultants and CROs.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 29, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 11, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 14, 2014 | Late filing | Notification of late filing |
| Jul 14, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 11, 2014 | Name change | Name changed from VENTRUS BIOSCIENCES INC to ASSEMBLY BIOSCIENCES, INC. |
| Nov 13, 2012 | Late filing | Notification of late filing |
| Nov 18, 2011 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 31, 2011 | Late filing | Notification of late filing |
| Jan 20, 2011 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 17, 2010 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 10, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |